Redhill Biopharma Ltd. RDHL
0.50
(0.02)
(3.85%)
as of 25 Sep
- Market cap
- $3.2M
- P/E
- 0.0×
Follow RDHL
| Jun '25 | Jun '24 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | (181.89%) | 294.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 7.59% | (4.22%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | (858.65%) | (102.41%) | |
Average Days of Receivables |
0.00 | 0.00 | 34.67 | 53.08 | |
Free Cash Flow per Share |
0.00 | 0.00 | (1.70) | (2.65) | |
Free Cash Flow |
(36.11) | (33.53) | (33.53) | (32.15) | |
Capital Expenditures |
(0.01) | (0.03) | (0.19) | — | |
Piotroski F-Score |
— | — | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
2,604.16% | (414.75%) | (152.19%) | (85.43%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.67 | 2.87 | |
Accounts Payable Turnover |
0.00 | 0.00 | 5.29 | 5.34 | |
Inventory Turnover |
0.00 | 0.00 | 2.38 | 2.67 | |
Average Days of Payables |
0.00 | 0.00 | 57.33 | 59.24 | |
Days of Inventory on Hand |
0.00 | 0.00 | 90.98 | 79.50 | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 16.53% | 11.23% | |
Selling, General and Administrative Expense of Revenue |
— | — | 144.88% | 115.54% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 12.25% | 7.45% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | (4.33) | 6.75 | |
Depreciation/Fixed assets |
492.78 | 434.90 | 268.87 | 10.28 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
— | — | 1.55 | 3.88 | |
Operating CF per Share |
0.00 | 0.00 | (1.70) | (2.65) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Net Profit Margin |
— | — | 25.20% | (10.10%) |
Columns are period end dates